[1] JIANG M,HU Y,LIN G,et al.Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma:clinical trials,efficacy and future directions［J］.Front Immunol,2023,14:1177085.
[2] 赫捷,邵康.中国食管癌流行病学现状、诊疗现状及未来对策［J］.中国癌症杂志,2011,21(7):4.
HE J,SHAO K.The epidemiology,current status of management,challenge and future strategy for esophageal cancer in China［J］.China Oncology,2011,21(7):4.
[3] WU Y,SONG Y,WANG R,et al.Molecular mechanisms of tumor resistance to radiotherapy［J］.Mol Cancer,2023,22(1):96.
[4] 地力亚尔·吾斯曼江,王岩,张玉俊，等.2006-2020年中国食管癌死亡趋势及其年龄-时期-队列模型分析［J］.现代肿瘤医学,2023,31(07):1323-1329.
DILIYAER W,WANG Y,ZHANG YJ,et al.Mortality trend of esophageal cancer in China from 2006 to 2020 and its age-period-cohort model analysis［J］.Modern Oncology,2023,31(07):1323-1329.
[5] WANG X,WANG P,HUANG X,et al.Biomarkers for immunotherapy in esophageal cancer［J］.Front Immunol,2023,14:1117523.
[6] JOHNSON DB,REYNOLDS KL,SULLIVAN RJ,et al.Immune checkpoint inhibitor toxicities:systems-based approaches to improve patient care and research［J］.Lancet Oncol,2020,21(8):e398-e404.
[7] LIU W,HUO G,CHEN P.Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics:a meta-analysis［J］.Immunotherapy,2023,15(10):751-771.
[8] PAPADAKOS SP,ARVANITAKIS K,STERGIOU IE,et al.The role of TLR4 in the immunotherapy of hepatocellular carcinoma:can we teach an old dog new tricks［J］.Cancers (Basel),2023,15(10):2795.
[9] YAN C,HUANG H,ZHENG Z,et al.Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer［J］.Front Immunol,2023,14:1138054.
[10] LIN M,XU Q,LUO Y,et al.Bakuchiol inhibits lung cancer by modulating tumor microenvironment and the expression of PD-L1［J］.J Biochem Mol Toxicol,2023:e23401.
[11] LIU G,LUO P.Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy［J］.Front Immunol,2023,14:1208788.
[12] 丁天皓,廖成成,李萍,等.IFN-γ在口腔鳞状细胞癌组织中的表达及功能研究进展［J］.重庆医学,2023,52(3):5.
DING TH,LIAO CC,LI P,et al.Research progress on the expression and function of IFN-γ in oral squamous cell carcinoma［J］.Chongqing Medicine,2023,52(3):5.
[13] DE GEORGE DJ,GE T,KRISHNAMURTHY B,et al.Inflammation versus regulation:how interferon-gamma contributes to type 1 diabetes pathogenesis［J］.Front Cell Dev Biol,2023,11:1205590.
[14] WU Q,ZHANG W,WANG Y,et al.MAGE-C3 promotes cancer metastasis by inducing epithelial-mesenchymal transition and immunosuppression in esophageal squamous cell carcinoma［J］.Cancer Commun (Lond),2021,41(12):1354-1372.
[15] 陈慧聪,刘运江,赵继东,等.IFN-γ通过下调CXCL8抑制食管鳞状细胞癌的增殖和迁移［J］.肿瘤防治研究,2022,49(3):5.
CHEN HC,LIU YJ,ZHAO JD,et al.IFN-γ inhibits proliferation and migration of esophageal squamous cell carcinoma by downregulating CXCL8 expression［J］.Cancer Res Prev Treat,2022,49(3):5.
[16] GUAN X,POLESSO F,WANG C,et al.Androgen receptor activity in T cells limits checkpoint blockade efficacy［J］.Nature,2022,606(7915):791-796.
[17] DOKI Y,AJANI JA,KATO K,et al.Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma［J］.N Engl J Med,2022,386(5):449-462.
[18] MAFUNE K,TANAKA Y.Influence of multimodality therapy on the cellular immunity of patients with esophageal cancer［J］.Ann Surg Oncol,2000,7(8):609-616.
[19] THELEN M,KELLER D,LEHMANN J,et al.Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells［J］.J Immunother Cancer,2022,10(12):e005200.
[20] SUKEDA M,PRAKASH H,NAGASAWA T,et al.Non-specific cytotoxic cell receptor protein-1 (NCCRP-1) is involved in anti-parasite innate CD8(+) T cell-mediated cytotoxicity in ginbuna crucian carp［J］.Fish Shellfish Immunol,2023,139:108904.
[21] CHEN DS,MELLMAN I.Elements of cancer immunity and the cancer-immune set point［J］.Nature,2017,541(7637):321-330.
[22] BAO N,FU B,ZHONG X,et al.Role of the CXCR6/CXCL16 axis in autoimmune diseases［J］.Int Immunopharmacol,2023,121:110530.
[23] CUI C,CRAFT J,JOSHI NS.T follicular helper cells in cancer,tertiary lymphoid structures,and beyond［J］.Semin Immunol,2023,69:101797.
[24] TAWBI HA,EROGLU Z,ANDERS CK,et al.Nivolumab plus ipilimumab in melanoma brain metastases - Authors' reply［J］.Lancet Oncol,2022,23(2):e54.
[25] 李恭泰,周艳琳.PD-1/PD-L1免疫检查点抑制剂治疗晚期食管癌的研究进展［J］.医学综述,2021,27(15):7.
LI GT,ZHOU YL.Research progress of PD-1/PD-L1 immune checkpoint inhibitors in advanced esophageal cancer［J］.Medical Recapitulate,2021,27(15):7.
[26] 路遥,孟祥瑞,许孟丽,等.PD-1/PD-L1抑制剂在食管癌临床研究进展［J］.食管疾病,2020,2(3):6.
LU Y，MENG XR，XU ML,et al.Clinical research progress of PD-1/PD-L1 inhibitors in esophageal cancer［J］.Journal of Esophageal Diseases,2020,2(3):6.
[27] CHEN G,HUANG AC,ZHANG W,et al.Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response［J］.Nature,2018,560(7718):382-386.
[28] 郭琪,姚昶,郭宇飞.血清IL1β,IL10,IFNγ在乳腺肿瘤定性诊断中价值及与预后相关性研究［J］.分子诊断与治疗杂志,2020,12(3):5.
GUO Q,YAO C,GUO YF.Serum IL1β,IL10 and IFNγ in the qualitative diagnosis of breast tumors and their correlation with prognosis［J］.J Mol Diagn Ther,2020,12(3):5.